Bruce Larson

Bruce A. Larson, PhD

Research Professor, Global Health - Boston University School of Public Health


Dr. Larson is an applied economist with the Department of Global Health. Dr. Larson has conducted research activities in about 25 countries over the past 30 years, mainly in Africa, the former Soviet Union and the US. Before joining Boston University, Larson was an Associate Professor in the Department of Agricultural and Resource Economics at the University of Connecticut, a Research Associate with the Harvard Institute for International Development, a Research Fellow with Winrock International, and an Agricultural Economist with the U.S. Department of Agriculture. As part of these activities, he was based in Tallinn, Riga, and Moscow during 1994-1997 and Nairobi during 2005-2006.

Since joining Boston University, his research has focused on economic evaluations of public health programs and interventions in clinical and community settings with experimental and quasi-experimental designs. Most of this evaluation work has been based on primary data collected in collaboration with colleagues and institutions in the country of focus (e.g., the Kenya Medical Research Institute/ Walter Reed Project, the Health Economics and Epidemiology Office of the University of Witwatersrand, and the Zambia Centre for Applied Health Research and Development). His evaluation research has addressed a range of topics, such as the impacts of HIV treatment on labor productivity, costs and usefulness of point-of-care technologies (CD4 tests, rapid syphilis tests, rapid malaria tests), costs of HIV care and treatment, and improving delivery of prevention of mother-to-child transmission).


  • University of Wisconsin Madison, PhD Field of Study: Economics
  • University of Wisconsin Madison, MA Field of Study: Economics
  • University of Wisconsin Madison, BA Field of Study: Economics

Classes Taught

  • SPHGH762
  • SPHGH815
  • SPHPH717


  • Published on 4/25/2023

    Larson BA, Tsikhutsu I, Bii M, Halim N, Agaba P, Sugut W, Muli J, Sawe F. The effects of revised peer-counselor support on the PMTCT cascade of care: results from a cluster-randomized trial in Kenya (the EMMA study). BMC Infect Dis. 2023 Apr 25; 23(1):257. PMID: 37098468.

    Read At: PubMed
  • Published on 2/1/2022

    Rajasingham R, Nalintya E, Israelski DM, Meya DB, Larson BA, Boulware DR. Cost-effectiveness of single-dose AmBisome pre-emptive treatment for the prevention of cryptococcal meningitis in African low and middle-income countries. Med Mycol. 2022 Feb 01; 60(2). PMID: 35026017.

    Read At: PubMed
  • Published on 7/1/2021

    Long LC, Rosen S, Nichols B, Larson BA, Ndlovu N, Meyer-Rath G. Getting resources to those who need them: the evidence we need to budget for underserved populations in sub-Saharan Africa. J Int AIDS Soc. 2021 07; 24 Suppl 3:e25707. PMID: 34189873.

    Read At: PubMed
  • Published on 6/4/2021

    Larson B, Shroufi A, Muthoga C, Oladele R, Rajasingham R, Jordan A, Jarvis JN, Chiller TM, Govender NP. Induction-phase treatment costs for cryptococcal meningitis in high HIV-burden African countries: New opportunities with lower costs. Wellcome Open Res. 2021; 6:140. PMID: 35706922.

    Read At: PubMed
  • Published on 3/18/2021

    Larson BA, Pascoe SJS, Huber A, Long LC, Murphy J, Miot J, Fraser-Hurt N, Fox MP, Rosen S. Fast-track treatment initiation counselling in South Africa: A cost-outcomes analysis. PLoS One. 2021; 16(3):e0248551. PMID: 33735206.

    Read At: PubMed
  • Published on 3/10/2021

    Tenforde MW, Muthoga C, Ponatshego P, Ngidi J, Mine M, Greene G, Jordan A, Chiller T, Larson BA, Jarvis JN. Cost-effectiveness of cryptococcal antigen screening at CD4 counts of 101-200 cells/µL in Botswana. Wellcome Open Res. 2021; 6:55. PMID: 35087954.

    Read At: PubMed
  • Published on 1/1/2021

    Radford, Arden Geddes, Jeffrey A. Gallagher, Kevin Larson, Bruce A. Open-source methods for estimating health risks of fine particulate matter from coal-fired power plants: A demonstration from Karachi, Pakistan. Environmental Impact Assessment Review. 2021; 91:106638.

    Read At: Custom
  • Published on 9/6/2020

    Brennan A, Maskew M, Larson BA, Tsikhutsu I, Bii M, Vezi L, Fox M, Venter WDF, Ehrenkranz PD, Rosen S. Prevalence of TB symptoms, diagnosis and treatment among people living with HIV (PLHIV) not on ART presenting at outpatient clinics in South Africa and Kenya: baseline results from a clinical trial. BMJ Open. 2020 09 06; 10(9):e035794. PMID: 32895266.

    Read At: PubMed
  • Published on 8/1/2020

    Yukich JO, Scott C, Silumbe K, Larson BA, Bennett A, Finn TP, Hamainza B, Conner RO, Porter TR, Keating J, Steketee RW, Eisele TP, Miller JM. Cost-Effectiveness of Focal Mass Drug Administration and Mass Drug Administration with Dihydroartemisinin-Piperaquine for Malaria Prevention in Southern Province, Zambia: Results of a Community-Randomized Controlled Trial. Am J Trop Med Hyg. 2020 08; 103(2_Suppl):46-53. PMID: 32618249.

    Read At: PubMed
  • Published on 7/1/2020

    Larson BA, Pascoe SJ, Huber A, Long LC, Murphy J, Miot J, Fox MP, Fraser-Hurt N, Rosen S. Will differentiated care for stable HIV patients reduce healthcare systems costs? J Int AIDS Soc. 2020 07; 23(7):e25541. PMID: 32686911.

    Read At: PubMed

News & In the Media